investors & media

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases

9/23/2020

EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 23, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease

Read more
9/22/2020

FDA set a target action date of March 27, 2021   Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 22, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc .

Read more
9/2/2020

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare Conference , Thursday, September 10 , at 4:00 pm ET Morgan

Read more